TY - JOUR
T1 - Outcomes and Factors AssociatedWith Prehospital Treatment of Pediatric Anaphylaxis
AU - Trainor, Jennifer L.
AU - Pittsenbarger, Zachary E.
AU - Joshi, Deepa
AU - Adler, Mark D.
AU - Smith, Bridget
AU - Gupta, Ruchi S.
N1 - Funding Information:
R.S.G. has received research support from the National Institute of Health (R21 ID No. AI135705, R01 ID No. AI130348, U01 ID No. AI138907), Allergy and Asthma Network, Rho Inc, Stanford Sean N. Parker Center for Allergy Research, Northwestern University Clinical and Translational Sciences Institute, Miller Family Foundation, Melchiorre Family Foundation, Aimmune Therapeutics, Mylan Specialty L.P., UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; is employed by Ann & Robert H. Lurie Children’s Hospital of Chicago; is a Professor of Pediatrics at Northwestern University; and serves as a medical consultant/advisor for Before Brands, Pfizer, Kaléo Inc, and DBV Technologies.
Funding Information:
Funding Source: This study was supported by an unrestricted grant from Mylan Pharmaceuticals.
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Objective: Anaphylaxis is a potentially life-threatening reaction requiring prompt treatment with intramuscular epinephrine (EPI). We sought to describe presenting features of pediatric anaphylaxis and compare patient characteristics and outcomes of children treated with prehospital EPI with those untreated. Methods: We abstracted data from emergency department (ED) records for children meeting the National Institute of Allergy & Infectious Disease criteria for anaphylaxis (2015-2017) in one tertiary care children's hospital. We analyzed associations between patient characteristics and outcomes and receipt of prehospital EPI using descriptive statistics and multivariate logistic regression. Results: Of 414 children presenting with anaphylaxis, 39.4%received IM EPI and 62.1% received antihistamines before hospital arrival. Children with Medicaid received pre-emergency department EPI less frequently than did children with private insurance (24.5%vs 43.8%, P = 0.001). Factors positively associated with prehospital EPI administration were history of food allergy (odds ratio [OR], 4.4 [95% confidence interval {CI}, 2.4-8.2]) or arrival by emergency medical services (OR, 8.0 [95% CI, 4.2-15.0]). Medicaid insurance was associated with decreased odds of prehospital EPI (OR, 0.33 [95% CI, 0.16-0.66]) and prehospital H1- antihistamine use (OR, 0.30 [95% CI, 0.17-0.56]). Prehospital EPI treatment was also associated with decreased rates of observation (37% vs 63%), inpatient admission (38% vs 62%), and intensive care unit admission (20% vs 80%) compared with no pretreatment (P = 0.03). Conclusions: Prehospital treatmentwith EPI remains low, and barriers to optimal treatment are more pronounced in children with public insurance. Prehospital treatmentwith EPI was associated with decreasedmorbidity including hospitalization and intensive care unit admission.
AB - Objective: Anaphylaxis is a potentially life-threatening reaction requiring prompt treatment with intramuscular epinephrine (EPI). We sought to describe presenting features of pediatric anaphylaxis and compare patient characteristics and outcomes of children treated with prehospital EPI with those untreated. Methods: We abstracted data from emergency department (ED) records for children meeting the National Institute of Allergy & Infectious Disease criteria for anaphylaxis (2015-2017) in one tertiary care children's hospital. We analyzed associations between patient characteristics and outcomes and receipt of prehospital EPI using descriptive statistics and multivariate logistic regression. Results: Of 414 children presenting with anaphylaxis, 39.4%received IM EPI and 62.1% received antihistamines before hospital arrival. Children with Medicaid received pre-emergency department EPI less frequently than did children with private insurance (24.5%vs 43.8%, P = 0.001). Factors positively associated with prehospital EPI administration were history of food allergy (odds ratio [OR], 4.4 [95% confidence interval {CI}, 2.4-8.2]) or arrival by emergency medical services (OR, 8.0 [95% CI, 4.2-15.0]). Medicaid insurance was associated with decreased odds of prehospital EPI (OR, 0.33 [95% CI, 0.16-0.66]) and prehospital H1- antihistamine use (OR, 0.30 [95% CI, 0.17-0.56]). Prehospital EPI treatment was also associated with decreased rates of observation (37% vs 63%), inpatient admission (38% vs 62%), and intensive care unit admission (20% vs 80%) compared with no pretreatment (P = 0.03). Conclusions: Prehospital treatmentwith EPI remains low, and barriers to optimal treatment are more pronounced in children with public insurance. Prehospital treatmentwith EPI was associated with decreasedmorbidity including hospitalization and intensive care unit admission.
KW - Anaphylaxis
KW - Disparities
KW - Food allergy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85117745968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117745968&partnerID=8YFLogxK
U2 - 10.1097/PEC.0000000000002146
DO - 10.1097/PEC.0000000000002146
M3 - Article
C2 - 32544141
AN - SCOPUS:85117745968
SN - 0749-5161
VL - 38
SP - E69-E74
JO - Pediatric emergency care
JF - Pediatric emergency care
IS - 1
ER -